Table of Contents Author Guidelines Submit a Manuscript
Advances in Hematology
Volume 2015, Article ID 612567, 6 pages
http://dx.doi.org/10.1155/2015/612567
Review Article

Protein Kinase CK2: A Targetable BCR-ABL Partner in Philadelphia Positive Leukemias

1Department of Clinical and Biological Sciences, University of Turin, 10043 Orbassano, Italy
2Department of Oncology, University of Turin, 10043 Orbassano, Italy

Received 27 October 2015; Accepted 20 December 2015

Academic Editor: Estella M. Matutes

Copyright © 2015 Alessandro Morotti et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. E. Maino, R. Sancetta, P. Viero et al., “Current and future management of Ph/BCR-ABL positive ALL,” Expert Review of Anticancer Therapy, vol. 14, no. 6, pp. 723–740, 2014. View at Publisher · View at Google Scholar · View at Scopus
  2. G. Saglio, A. Morotti, G. Mattioli et al., “Rational approaches to the design of therapeutics targeting molecular markers: the case of chronic myelogenous leukemia,” Annals of the New York Academy of Sciences, vol. 1028, pp. 423–431, 2004. View at Publisher · View at Google Scholar · View at Scopus
  3. A. Morotti, C. Fava, and G. Saglio, “Milestones and monitoring,” Current Hematologic Malignancy Reports, vol. 10, no. 2, pp. 167–172, 2015. View at Publisher · View at Google Scholar
  4. J. V. Melo and D. J. Barnes, “Chronic myeloid leukaemia as a model of disease evolution in human cancer,” Nature Reviews Cancer, vol. 7, no. 6, pp. 441–453, 2007. View at Publisher · View at Google Scholar · View at Scopus
  5. K. M. Bernt and S. P. Hunger, “Current concepts in pediatric Philadelphia chromosome-positive acute lymphoblastic leukemia,” Frontiers in Oncology, vol. 4, article 54, 2014. View at Publisher · View at Google Scholar · View at Scopus
  6. E. Jabbour and H. Kantarjian, “Chronic myeloid leukemia: 2014 update on diagnosis, monitoring, and management,” American Journal of Hematology, vol. 89, no. 5, pp. 547–556, 2014. View at Publisher · View at Google Scholar · View at Scopus
  7. K. Sweet and V. Oehler, “Discontinuation of tyrosine kinase inhibitors in chronic myeloid leukemia: when is this a safe option to consider?” Hematology/the Education Program of the American Society of Hematology, vol. 2013, no. 1, pp. 184–188, 2013. View at Publisher · View at Google Scholar
  8. A. Morotti, C. Panuzzo, C. Fava, and G. Saglio, “Kinase-inhibitor-insensitive cancer stem cells in chronic myeloid leukemia,” Expert Opinion on Biological Therapy, vol. 14, no. 3, pp. 287–299, 2014. View at Publisher · View at Google Scholar · View at Scopus
  9. F. Pellicano, L. Mukherjee, and T. L. Holyoake, “Concise review: cancer cells escape from oncogene addiction: Understanding the mechanisms behind treatment failure for more effective targeting,” Stem Cells, vol. 32, no. 6, pp. 1373–1379, 2014. View at Publisher · View at Google Scholar · View at Scopus
  10. A. Hamilton, G. V. Helgason, M. Schemionek et al., “Chronic myeloid leukemia stem cells are not dependent on Bcr-Abl kinase activity for their survival,” Blood, vol. 119, no. 6, pp. 1501–1510, 2012. View at Publisher · View at Google Scholar · View at Scopus
  11. A. S. Corbin, A. Agarwal, M. Loriaux, J. Cortes, M. W. Deininger, and B. J. Druker, “Human chronic myeloid leukemia stem cells are insensitive to imatinib despite inhibition of BCR-ABL activity,” Journal of Clinical Investigation, vol. 121, no. 1, pp. 396–409, 2011. View at Publisher · View at Google Scholar · View at Scopus
  12. A. Hochhaus and H. Kantarjian, “The development of dasatinib as a treatment for Chronic Myeloid Leukemia (CML): from initial studies to application in newly diagnosed patients,” Journal of Cancer Research and Clinical Oncology, vol. 139, no. 12, pp. 1971–1984, 2013. View at Publisher · View at Google Scholar · View at Scopus
  13. K. Yang and L.-W. Fu, “Mechanisms of resistance to BCR-ABL TKIs and the therapeutic strategies: a review,” Critical Reviews in Oncology/Hematology, vol. 93, no. 3, pp. 27–292, 2015. View at Publisher · View at Google Scholar · View at Scopus
  14. M. Ruzzene and L. A. Pinna, “Addiction to protein kinase CK2: a common denominator of diverse cancer cells?” Biochimica et Biophysica Acta—Proteins and Proteomics, vol. 1804, no. 3, pp. 499–504, 2010. View at Publisher · View at Google Scholar · View at Scopus
  15. A. Venerando, M. Ruzzene, and L. A. Pinna, “Casein kinase: the triple meaning of a misnomer,” Biochemical Journal, vol. 460, no. 2, pp. 141–156, 2014. View at Publisher · View at Google Scholar · View at Scopus
  16. M. Montenarh, “Cellular regulators of protein kinase CK2,” Cell and Tissue Research, vol. 342, no. 2, pp. 139–146, 2010. View at Publisher · View at Google Scholar · View at Scopus
  17. L. A. Pinna, “Protein kinase CK2: a challenge to canons,” Journal of Cell Science, vol. 115, part 20, pp. 3873–3878, 2002. View at Publisher · View at Google Scholar · View at Scopus
  18. F. Piazza, S. Manni, M. Ruzzene, L. A. Pinna, C. Gurrieri, and G. Semenzato, “Protein kinase CK2 in hematologic malignancies: Reliance on a pivotal cell survival regulator by oncogenic signaling pathways,” Leukemia, vol. 26, no. 6, pp. 1174–1179, 2012. View at Publisher · View at Google Scholar · View at Scopus
  19. D. W. Litchfield, “Protein kinase CK2: structure, regulation and role in cellular decisions of life and death,” Biochemical Journal, vol. 369, no. 1, pp. 1–15, 2003. View at Publisher · View at Google Scholar · View at Scopus
  20. R. Battistutta and G. Lolli, “Structural and functional determinants of protein kinase CK2α: facts and open questions,” Molecular and Cellular Biochemistry, vol. 356, no. 1-2, pp. 67–73, 2011. View at Publisher · View at Google Scholar · View at Scopus
  21. J. S. Duncan and D. W. Litchfield, “Too much of a good thing: the role of protein kinase CK2 in tumorigenesis and prospects for therapeutic inhibition of CK2,” Biochimica et Biophysica Acta, vol. 1784, no. 1, pp. 33–47, 2008. View at Publisher · View at Google Scholar · View at Scopus
  22. D. C. Seldin, D. Y. Lou, P. Toselli, E. Landesman-Bollag, and I. Dominguez, “Gene targeting of CK2 catalytic subunits,” Molecular and Cellular Biochemistry, vol. 316, no. 1-2, pp. 141–147, 2008. View at Publisher · View at Google Scholar · View at Scopus
  23. D. Y. Lou, I. Dominguez, P. Toselli, E. Landesman-Bollag, C. O'Brien, and D. C. Seldin, “The alpha catalytic subunit of protein kinase CK2 is required for mouse embryonic development,” Molecular and Cellular Biology, vol. 28, no. 1, pp. 131–139, 2008. View at Publisher · View at Google Scholar · View at Scopus
  24. T. Buchou, M. Vernet, O. Blond et al., “Disruption of the regulatory β subunit of protein kinase CK2 in mice leads to a cell-autonomous defect and early embryonic lethality,” Molecular and Cellular Biology, vol. 23, no. 3, pp. 908–915, 2003. View at Publisher · View at Google Scholar · View at Scopus
  25. X. Xu, P. A. Toselli, L. D. Russell, and D. C. Seldin, “Globozoospermia in mice lacking the casein kinase II α′ catalytic subunit,” Nature Genetics, vol. 23, no. 1, pp. 118–121, 1999. View at Publisher · View at Google Scholar · View at Scopus
  26. D. W. Litchfield, G. Dobrowolska, and E. G. Krebs, “Regulation of casein kinase II by growth factors: a reevaluation,” Cellular and Molecular Biology Research, vol. 40, no. 5-6, pp. 373–381, 1994. View at Google Scholar · View at Scopus
  27. K. Niefind and O.-G. Issinger, “Conformational plasticity of the catalytic subunit of protein kinase CK2 and its consequences for regulation and drug design,” Biochimica et Biophysica Acta—Proteins and Proteomics, vol. 1804, no. 3, pp. 484–492, 2010. View at Publisher · View at Google Scholar · View at Scopus
  28. O. Filhol and C. Cochet, “Protein kinase CK2 in health and disease: cellular functions of protein kinase CK2: a dynamic affair,” Cellular and Molecular Life Sciences, vol. 66, no. 11-12, pp. 1830–1839, 2009. View at Publisher · View at Google Scholar · View at Scopus
  29. Y. Shi, B. E. Paluch, X. Wang, and X. Jiang, “PTEN at a glance,” Journal of Cell Science, vol. 125, no. 20, pp. 4687–4692, 2012. View at Publisher · View at Google Scholar · View at Scopus
  30. M. S. Song, L. Salmena, and P. P. Pandolfi, “The functions and regulation of the PTEN tumour suppressor,” Nature Reviews Molecular Cell Biology, vol. 13, no. 5, pp. 283–296, 2012. View at Publisher · View at Google Scholar · View at Scopus
  31. S. J. Miller, D. Y. Lou, D. C. Seldin, W. S. Lane, and B. G. Neel, “Direct identification of PTEN phosphorylation sites,” FEBS Letters, vol. 528, no. 1–3, pp. 145–153, 2002. View at Publisher · View at Google Scholar · View at Scopus
  32. F. Vazquez, S. R. Grossman, Y. Takahashi, M. V. Rokas, N. Nakamura, and W. R. Sellers, “Phosphorylation of the PTEN tail acts as an inhibitory switch by preventing its recruitment into a protein complex,” The Journal of Biological Chemistry, vol. 276, no. 52, pp. 48627–48630, 2001. View at Publisher · View at Google Scholar · View at Scopus
  33. F. Vazquez, S. Ramaswamy, N. Nakamura, and W. R. Sellers, “Phosphorylation of the PTEN tail regulates protein stability and function,” Molecular and Cellular Biology, vol. 20, no. 14, pp. 5010–5018, 2000. View at Publisher · View at Google Scholar · View at Scopus
  34. M.-M. Georgescu, K. H. Kirsch, T. Akagi, T. Shishido, and H. Hanafusa, “The tumor-suppressor activity of PTEN is regulated by its carboxyl-terminal region,” Proceedings of the National Academy of Sciences of the United States of America, vol. 96, no. 18, pp. 10182–10187, 1999. View at Publisher · View at Google Scholar · View at Scopus
  35. J. Torres and R. Pulido, “The tumor suppressor PTEN is phosphorylated by the protein kinase CK2 at its C terminus. Implications for PTEN stability to proteasome-mediated degradation,” Journal of Biological Chemistry, vol. 276, no. 2, pp. 993–998, 2001. View at Publisher · View at Google Scholar · View at Scopus
  36. F. Cordier, A. Chaffotte, E. Terrien et al., “Ordered phosphorylation events in two independent cascades of the PTEN C-tail revealed by NMR,” Journal of the American Chemical Society, vol. 134, no. 50, pp. 20533–20543, 2012. View at Publisher · View at Google Scholar · View at Scopus
  37. L. Odriozola, G. Singh, T. Hoang, and A. M. Chan, “Regulation of PTEN activity by its carboxyl-terminal autoinhibitory domain,” The Journal of Biological Chemistry, vol. 282, no. 32, pp. 23306–23315, 2007. View at Publisher · View at Google Scholar · View at Scopus
  38. A. Silva, J. A. Yunes, B. A. Cardoso et al., “PTEN posttranslational inactivation and hyperactivation of the PI3K/Akt pathway sustain primary T cell leukemia viability,” Journal of Clinical Investigation, vol. 118, no. 11, pp. 3762–3774, 2008. View at Publisher · View at Google Scholar · View at Scopus
  39. A. Silva, P. Y. Jotta, A. B. Silveira et al., “Regulation of PTEN by CK2 and Notch1 in primary T-cell acute lymphoblastic leukemia: Rationale for combined use of CK2- and γ-secretase inhibitors,” Haematologica, vol. 95, no. 4, pp. 674–678, 2010. View at Publisher · View at Google Scholar · View at Scopus
  40. A. M. Gomes, M. V. D. Soares, P. Ribeiro et al., “Adult B-cell acute lymphoblastic leukemia cells display decreased PTEN activity and constitutive hyperactivation of PI3K/Akt pathway despite high PTEN protein levels,” Haematologica, vol. 99, no. 6, pp. 1062–1068, 2014. View at Publisher · View at Google Scholar · View at Scopus
  41. L. R. Martins, Y. Perera, P. Lúcio, M. G. Silva, S. E. Perea, and J. T. Barata, “Targeting chronic lymphocytic leukemia using CIGB-300, a clinical-stage CK2-specific cell-permeable peptide inhibitor,” Oncotarget, vol. 5, no. 1, pp. 258–263, 2014. View at Publisher · View at Google Scholar · View at Scopus
  42. M. Shehata, S. Schnabl, D. Demirtas et al., “Reconstitution of PTEN activity by CK2 inhibitors and interference with the PI3-K/Akt cascade counteract the antiapoptotic effect of human stromal cells in chronic lymphocytic leukemia,” Blood, vol. 116, no. 14, pp. 2513–2521, 2010. View at Publisher · View at Google Scholar · View at Scopus
  43. I. M. Hanif, I. M. Hanif, M. A. Shazib, K. A. Ahmad, and S. Pervaiz, “Casein Kinase II: an attractive target for anti-cancer drug design,” International Journal of Biochemistry and Cell Biology, vol. 42, no. 10, pp. 1602–1605, 2010. View at Publisher · View at Google Scholar · View at Scopus
  44. G. Cozza, L. A. Pinna, and S. Moro, “Kinase CK2 inhibition: an update,” Current Medicinal Chemistry, vol. 20, no. 5, pp. 671–693, 2013. View at Publisher · View at Google Scholar · View at Scopus
  45. G. Cozza, L. A. Pinna, and S. Moro, “Protein kinase CK2 inhibitors: a patent review,” Expert Opinion on Therapeutic Patents, vol. 22, no. 9, pp. 1081–1097, 2012. View at Publisher · View at Google Scholar · View at Scopus
  46. G. Cozza, S. Zanin, S. Sarno et al., “Design, validation and efficacy of bisubstrate inhibitors specifically affecting ecto-CK2 kinase activity,” Biochemical Journal, vol. 471, no. 3, pp. 415–430, 2015. View at Publisher · View at Google Scholar
  47. C. Girardi, D. Ottaviani, L. A. Pinna, and M. Ruzzene, “Different persistence of the cellular effects promoted by protein kinase CK2 inhibitors CX-4945 and TDB,” BioMed Research International, vol. 2015, Article ID 185736, 9 pages, 2015. View at Publisher · View at Google Scholar
  48. E. Iori, M. Ruzzene, S. Zanin, S. Sbrignadello, L. A. Pinna, and P. Tessari, “Effects of CK2 inhibition in cultured fibroblasts from Type 1 Diabetic patients with or without nephropathy,” Growth Factors, vol. 33, no. 4, pp. 259–266, 2015. View at Publisher · View at Google Scholar
  49. G. Cozza, A. Venerando, S. Sarno, and L. A. Pinna, “The selectivity of CK2 inhibitor quinalizarin: a reevaluation,” BioMed Research International, vol. 2015, Article ID 734127, 9 pages, 2015. View at Publisher · View at Google Scholar
  50. A. Siddiqui-Jain, D. Drygin, N. Streiner et al., “CX-4945, an orally bioavailable selective inhibitor of protein kinase CK2, inhibits prosurvival and angiogenic signaling and exhibits antitumor efficacy,” Cancer Research, vol. 70, no. 24, pp. 10288–10298, 2010. View at Publisher · View at Google Scholar · View at Scopus
  51. V. Moucadel, R. Prudent, C. F. Sautel et al., “Antitumoral activity of allosteric inhibitors of protein kinase CK2,” Oncotarget, vol. 2, no. 12, pp. 997–1010, 2011. View at Publisher · View at Google Scholar · View at Scopus
  52. B. Guerra, J. Hochscherf, N. B. Jensen, and O. Issinger, “Identification of a novel potent, selective and cell permeable inhibitor of protein kinase CK2 from the NIH/NCI Diversity Set Library,” Molecular and Cellular Biochemistry, vol. 406, no. 1-2, pp. 151–161, 2015. View at Publisher · View at Google Scholar
  53. B. Guerra, T. D. L. Rasmussen, A. Schnitzler et al., “Protein kinase CK2 inhibition is associated with the destabilization of HIF-1α in human cancer cells,” Cancer Letters, vol. 356, no. 2, pp. 751–761, 2015. View at Publisher · View at Google Scholar · View at Scopus
  54. B. Guerra, M. Fischer, S. Schaefer, and O. Issinger, “The kinase inhibitor D11 induces caspase-mediated cell death in cancer cells resistant to chemotherapeutic treatment,” Journal of Experimental & Clinical Cancer Research, vol. 34, no. 1, article 125, 2015. View at Publisher · View at Google Scholar
  55. R. C. Prins, R. T. Burke, J. W. Tyner, B. J. Druker, M. M. Loriaux, and S. E. Spurgeon, “CX-4945, a selective inhibitor of casein kinase-2 (CK2), exhibits anti-tumor activity in hematologic malignancies including enhanced activity in chronic lymphocytic leukemia when combined with fludarabine and inhibitors of the B-cell receptor pathway,” Leukemia, vol. 27, no. 10, pp. 2094–2096, 2013. View at Publisher · View at Google Scholar · View at Scopus
  56. F. Buontempo, E. Orsini, L. R. Martins et al., “Cytotoxic activity of the casein kinase 2 inhibitor CX-4945 against T-cell acute lymphoblastic leukemia: targeting the unfolded protein response signaling,” Leukemia, vol. 28, no. 3, pp. 543–553, 2014. View at Publisher · View at Google Scholar · View at Scopus
  57. F. Phan-Dinh-Tuy, J. Henry, C. Boucheix, J. Y. Perrot, C. Rosenfeld, and A. Kahn, “Protein kinases in human leukemic cells,” American Journal of Hematology, vol. 19, no. 3, pp. 209–218, 1985. View at Publisher · View at Google Scholar · View at Scopus
  58. J.-K. Hériché and E. M. Chambaz, “Protein kinase CK2α is a target for the Abl and Bcr-Abl tyrosine kinases,” Oncogene, vol. 17, no. 1, pp. 13–18, 1998. View at Publisher · View at Google Scholar · View at Scopus
  59. S. Mishra, A. Reichert, J. Cunnick et al., “Protein kinase CKIIα interacts with the Bcr moiety of Bcr/Abl and mediates proliferation of Bcr/Abl-expressing cells,” Oncogene, vol. 22, no. 51, pp. 8255–8262, 2003. View at Publisher · View at Google Scholar · View at Scopus
  60. S. Mishra, V. Pertz, B. Zhang et al., “Treatment of P190 Bcr/Abl lymphoblastic leukemia cells with inhibitors of the serine/threonine kinase CK2,” Leukemia, vol. 21, no. 1, pp. 178–180, 2007. View at Publisher · View at Google Scholar · View at Scopus
  61. C. Borgo, L. Cesaro, V. Salizzato et al., “Aberrant signalling by protein kinase CK2 in imatinib-resistant chronic myeloid leukaemia cells: biochemical evidence and therapeutic perspectives,” Molecular Oncology, vol. 7, no. 6, pp. 1103–1115, 2013. View at Publisher · View at Google Scholar · View at Scopus
  62. A. Morotti, C. Panuzzo, S. Crivellaro et al., “BCR-ABL inactivates cytosolic PTEN through Casein Kinase II mediated tail phosphorylation,” Cell Cycle, vol. 14, no. 7, pp. 973–979, 2015. View at Publisher · View at Google Scholar
  63. A. Morotti, C. Panuzzo, S. Crivellaro et al., “BCR-ABL disrupts PTEN nuclear-cytoplasmic shuttling through phosphorylation-dependent activation of HAUSP,” Leukemia, vol. 28, no. 6, pp. 1326–1333, 2014. View at Publisher · View at Google Scholar · View at Scopus